Profile data is unavailable for this security.
About the company
EssilorLuxottica SA, formerly known as Essilor International Compagnie Generale D Optique SA, is a France-based ophthalmic company. The Company designs, manufactures and markets a range of lenses, frames and sunglasses to improve and protect eyesight. It also develops and markets equipment for prescription laboratories and instruments, and services for eye care professionals. It operates through three segments: Lenses and Optical Instruments, which includes corrective lenses, optical instruments intended for opticians and optometrists; Equipment, which includes machines and consumables used by plants and prescription laboratories, and Sunglasses & Readers, which encompasses non-prescription reading glasses and non-prescription sunglasses. The Company operates under a number of brands, including Ray-Ban, Oakley and Varilux, among others. The Company operates in Europe, North America, Asia Pacific, the Middle East, Africa and Latin America.
- Revenue in EUR (TTM)14.43bn
- Net income in EUR85.00m
- Incorporated1993
- Employees144.51k
- LocationEssilorLuxottica SA147 rue de ParisCHARENTON-LE-PONT 94220FranceFRA
- Phone+33 149774224
- Fax+33 149774420
- Websitehttps://www.essilorluxottica.com/
Mergers & acquisitions
| Acquired company | EL:PAR since announced | Transaction value |
|---|---|---|
| Walman Optical Co | 16.11% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Smith & Nephew plc | 3.87bn | 380.09m | 15.96bn | 17.91k | 42.01 | 3.55 | 18.62 | 4.12 | 0.37 | 0.37 | 3.77 | 4.38 | 0.449 | 0.8448 | 3.59 | 184,953.10 | 4.41 | 7.91 | 5.25 | 9.57 | 69.39 | 72.89 | 9.82 | 13.70 | 1.76 | 11.02 | 0.4114 | 46.96 | -11.25 | -0.3214 | -25.33 | 1.79 | 4.35 | -5.90 |
| Carl Zeiss Meditec AG | 1.39bn | 159.08m | 16.47bn | 3.37k | 102.96 | 10.65 | -- | 11.86 | 1.79 | 1.79 | 15.57 | 17.28 | 0.6458 | 2.04 | 8.29 | 421,848.60 | 7.44 | 7.94 | 8.94 | 9.96 | 56.62 | 55.46 | 11.52 | 10.17 | 3.39 | 7.48 | 0.1185 | 36.70 | -8.49 | 5.13 | -23.39 | 14.46 | 21.81 | 5.64 |
| Sonova Holding AG | 2.40bn | 536.88m | 20.96bn | 14.51k | 38.38 | 8.08 | 29.03 | 8.72 | 9.18 | 9.18 | 41.15 | 43.59 | 0.4998 | 2.54 | 6.34 | 179,342.40 | 11.24 | 10.33 | 14.61 | 13.10 | 72.26 | 70.93 | 22.49 | 16.56 | 1.85 | 29.99 | 0.3481 | 23.30 | -10.80 | 4.66 | 31.95 | 10.41 | 1.44 | 8.79 |
| Straumann Holding AG | 1.32bn | 84.35m | 24.25bn | 7.02k | 290.93 | 21.76 | 136.85 | 18.40 | 5.67 | 5.67 | 89.54 | 75.81 | 0.5774 | 1.76 | 4.24 | 203,257.50 | 3.74 | 13.46 | 4.65 | 16.25 | 72.22 | 75.29 | 6.47 | 18.55 | 2.47 | 7.61 | 0.3652 | 34.41 | -10.67 | 12.29 | -70.22 | 5.25 | 18.46 | 7.53 |
| Coloplast A/S | 2.49bn | 578.73m | 29.85bn | 12.50k | 55.57 | 34.42 | 43.31 | 12.00 | 20.17 | 20.17 | 86.69 | 32.57 | 1.29 | 2.81 | 5.80 | 1,488,694.00 | 29.91 | 31.57 | 53.60 | 54.57 | 68.04 | 67.88 | 23.26 | 22.68 | 0.6476 | 66.89 | 0.3729 | 89.51 | 3.37 | 5.92 | 8.37 | 36.09 | 8.58 | 7.57 |
| Koninklijke Philips NV | 19.20bn | 1.12bn | 37.40bn | 77.34k | 34.03 | -- | 14.62 | 1.95 | 1.20 | 1.27 | 20.82 | -- | -- | -- | -- | 235,354.00 | -- | 3.98 | -- | 5.69 | 43.86 | 46.27 | 5.88 | 6.03 | -- | 80.48 | -- | -- | 0.272 | 3.06 | 0.9275 | 52.53 | 2.61 | 1.63 |
| Sartorius Stedim Biotech SA | 2.39bn | 474.45m | 42.58bn | 8.75k | 89.81 | 25.52 | 70.59 | 17.79 | 5.14 | 5.14 | 25.94 | 18.10 | 0.8329 | 2.21 | 9.01 | 316,280.90 | 16.70 | 13.93 | 21.77 | 18.30 | 53.57 | 51.71 | 20.05 | 16.82 | 0.8233 | 35.50 | 0.2648 | 20.42 | 32.59 | 16.65 | 52.60 | 24.84 | 24.61 | 15.33 |
| Siemens Healthineers AG | 15.02bn | 1.57bn | 61.81bn | 54.50k | 36.55 | 4.18 | 25.53 | 4.12 | 1.50 | 1.50 | 14.41 | 13.10 | 0.5026 | 3.84 | 4.25 | 278,166.70 | 5.32 | 6.64 | 7.00 | 10.98 | 38.51 | 40.22 | 10.58 | 10.08 | 2.30 | 53.88 | 0.032 | -- | -0.3995 | 2.25 | -9.96 | 2.02 | 9.37 | -- |
| EssilorLuxottica SA | 14.43bn | 85.00m | 68.52bn | 144.51k | 881.66 | 2.10 | 29.91 | 4.75 | 0.1759 | 0.1759 | 32.87 | 73.84 | 0.2751 | 2.97 | 6.45 | 99,846.38 | 0.2841 | 2.82 | 0.3238 | 3.36 | 57.81 | 60.53 | 1.03 | 7.47 | 1.91 | 10.64 | 0.2662 | 59.39 | -17.03 | 16.53 | -92.11 | -35.42 | 14.73 | 14.97 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2021 | 7.37m | 1.67% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2021 | 7.11m | 1.61% |
| Norges Bank Investment Managementas of 31 Dec 2020 | 6.62m | 1.50% |
| Capital Research & Management Co. (Global Investors)as of 31 Mar 2021 | 6.04m | 1.37% |
| BlackRock Fund Advisorsas of 08 Jul 2021 | 4.48m | 1.02% |
| Massachusetts Financial Services Co.as of 28 May 2021 | 3.91m | 0.88% |
| Amundi Asset Management SA (Investment Management)as of 31 Dec 2020 | 3.56m | 0.81% |
| Comgest SAas of 30 Apr 2021 | 2.93m | 0.66% |
| BlackRock Advisors (UK) Ltd.as of 08 Jul 2021 | 2.83m | 0.64% |
| TIAA-CREF Investment Management LLCas of 31 May 2021 | 2.72m | 0.62% |
